Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Change in Acquisitions & Divestments (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Change in Acquisitions & Divestments readings, the most recent being $101.5 million for Q4 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments rose 30.68% to $101.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $286.7 million, a 12.22% decrease, with the full-year FY2025 number at $262.9 million, down 31.45% from a year prior.
  • Change in Acquisitions & Divestments hit $101.5 million in Q4 2025 for Enanta Pharmaceuticals, up from $72.4 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $134.5 million in Q4 2023 to a low of $26.7 million in Q1 2022.
  • Median Change in Acquisitions & Divestments over the past 5 years was $75.0 million (2023), compared with a mean of $78.1 million.
  • Biggest five-year swings in Change in Acquisitions & Divestments: surged 210.73% in 2023 and later plummeted 76.51% in 2024.
  • Enanta Pharmaceuticals' Change in Acquisitions & Divestments stood at $108.8 million in 2021, then dropped by 4.29% to $104.1 million in 2022, then increased by 29.22% to $134.5 million in 2023, then crashed by 42.28% to $77.6 million in 2024, then soared by 30.68% to $101.5 million in 2025.
  • The last three reported values for Change in Acquisitions & Divestments were $101.5 million (Q4 2025), $72.4 million (Q3 2025), and $59.7 million (Q2 2025) per Business Quant data.